Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-001 + QS-21 long-term extension in mild to moderate Alzheimer's disease
2009-010922-21Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vanutide cridificar and QS-21 in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Long-term safety and tolerability, Safety assessments and 1 more. Started Jun 2009; status: completed.
02
Drugs
vanutide cridificarQS-21
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-010922-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010922-21.